Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK?
Matthew P. Vincenti, Constance E. Brinckerhoff
Matthew P. Vincenti, Constance E. Brinckerhoff
Published July 15, 2001
Citation Information: J Clin Invest. 2001;108(2):181-183. https://doi.org/10.1172/JCI13508.
View: Text | PDF
Commentary

The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK?

  • Text
  • PDF
Abstract

Authors

Matthew P. Vincenti, Constance E. Brinckerhoff

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
IL-1 activation of MAPK pathways. IL-1 binds to its cellular receptor an...
IL-1 activation of MAPK pathways. IL-1 binds to its cellular receptor and activates receptor-associated proteins (red), such as IRAK, TRAF6, and TAK1. The result is activation of several MAPK kinases (MKK6, MKK4, MKK7, and MEK1; green), which phosphorylate and active the MAPKs p38, JNK, and ERK (blue). SB203580 inhibits the p38 kinases, while PD98059 blocks activation of MEK1, and as a consequence ERK activation. SP600125 is a novel inhibitor of JNK, described by Han et al. in a recent issue of the JCI (13).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts